Incretin‐based therapies for individuals with obesity and heart failure with mildly reduced or preserved ejection fraction: A systematic review and meta‐analysis of randomized controlled trials
Study context
- Population
- Patients with obesity and HF with mildly reduced or preserved ejection fraction (HFpEF); Randomised clinical trials (RCTs) searched in PubMed, EMBASE and Web of Science through December 2024
- Participants
- 7,282 patients6 RCTs
- Comparison
- Incretin-based therapies vs placebo
- Outcome
- Clinical outcomes
Methodological detailsinverse variance random-effects model
- Inverse variance random-effects model
Pooled result
As reported in the abstract
IBTs vs PlaceboEstimate (95% CI)
Cardiovascular death or worsening HF; I2 = 0%
HR 0.74(0.63–0.88)
Worsening HF events; I2 = 16%
HR 0.62(0.47–0.81)
All-cause mortality; I2 = 0%
OR 0.81(0.67–0.99)
Further pooled results
- Incretin-based therapies (IBTs) improved quality of life, functional status, systolic blood pressure and weight loss
Original publication
Incretin‐based therapies for individuals with obesity and heart failure with mildly reduced or preserved ejection fraction: A systematic review and meta‐analysis of randomized controlled trials. Diabetes Obes Metab. Published 11 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →